Medscape |
FDA approves Cinqair to treat severe asthma
FDA.gov The U.S. Food and Drug Administration today approved Cinqair (reslizumab) for use with other asthma medicines for the maintenance treatment of severe asthma in patients aged 18 years and older. Cinqair is approved for patients who have a history of … Reslizumab (Cinqair) Approved to Treat Severe Asthma FDA Approves Reslizumab for Adults With Severe Asthma FDA clears Teva's asthma med Cinqair |
View full post on asthma – Google News